JP2019517511A - 腫瘍を処置する方法において使用するための抗ｐｄ−１抗体 - Google Patents

腫瘍を処置する方法において使用するための抗ｐｄ−１抗体 Download PDF

Info

Publication number
JP2019517511A
JP2019517511A JP2018563090A JP2018563090A JP2019517511A JP 2019517511 A JP2019517511 A JP 2019517511A JP 2018563090 A JP2018563090 A JP 2018563090A JP 2018563090 A JP2018563090 A JP 2018563090A JP 2019517511 A JP2019517511 A JP 2019517511A
Authority
JP
Japan
Prior art keywords
antibody
tumor
stk11
months
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018563090A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019517511A5 (enExample
Inventor
ロビン・エドワーズ
ハン・チャン
ミシェル・クリアリー
ピーター・エム・シャボ
ジョセフ・ディ・シュスタコウスキー
パトリック・ビタツカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2019517511A publication Critical patent/JP2019517511A/ja
Publication of JP2019517511A5 publication Critical patent/JP2019517511A5/ja
Priority to JP2022146466A priority Critical patent/JP2022188071A/ja
Priority to JP2025022545A priority patent/JP2025081454A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2018563090A 2016-06-03 2017-06-02 腫瘍を処置する方法において使用するための抗ｐｄ−１抗体 Pending JP2019517511A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022146466A JP2022188071A (ja) 2016-06-03 2022-09-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体
JP2025022545A JP2025081454A (ja) 2016-06-03 2025-02-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662345658P 2016-06-03 2016-06-03
US62/345,658 2016-06-03
PCT/US2017/035798 WO2017210624A1 (en) 2016-06-03 2017-06-02 Anti-pd-1 antibody for use in a method of treating a tumor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022146466A Division JP2022188071A (ja) 2016-06-03 2022-09-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体

Publications (2)

Publication Number Publication Date
JP2019517511A true JP2019517511A (ja) 2019-06-24
JP2019517511A5 JP2019517511A5 (enExample) 2020-07-09

Family

ID=59067919

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018563090A Pending JP2019517511A (ja) 2016-06-03 2017-06-02 腫瘍を処置する方法において使用するための抗ｐｄ−１抗体
JP2022146466A Pending JP2022188071A (ja) 2016-06-03 2022-09-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体
JP2025022545A Pending JP2025081454A (ja) 2016-06-03 2025-02-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022146466A Pending JP2022188071A (ja) 2016-06-03 2022-09-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体
JP2025022545A Pending JP2025081454A (ja) 2016-06-03 2025-02-14 腫瘍を処置する方法において使用するための抗ｐｄ－１抗体

Country Status (6)

Country Link
US (3) US20200325226A1 (enExample)
EP (1) EP3464369A1 (enExample)
JP (3) JP2019517511A (enExample)
KR (3) KR20250107295A (enExample)
CN (1) CN109476753A (enExample)
WO (1) WO2017210624A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013263076B2 (en) 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2016176504A1 (en) 2015-04-28 2016-11-03 Bristol-Myers Squibb Company Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody
JP2018514550A (ja) 2015-04-28 2018-06-07 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置
CA2991976A1 (en) 2015-07-13 2017-01-19 Cytomx Therapeutics, Inc. Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof
MX392711B (es) 2015-08-11 2025-03-24 Wuxi Biologics Ireland Ltd Anticuerpos anti-pd-1 novedosos.
CN108350081A (zh) 2015-11-18 2018-07-31 百时美施贵宝公司 使用抗pd-1抗体和抗ctla-4抗体的组合治疗肺癌
JP7780857B2 (ja) * 2017-06-01 2025-12-05 ブリストル－マイヤーズ スクイブ カンパニー 抗ｐｄ－１抗体を用いる腫瘍の治療方法
WO2019157124A1 (en) * 2018-02-08 2019-08-15 Bristol-Myers Squibb Company Combination of a tetanus toxoid, anti-ox40 antibody and/or anti-pd-1 antibody to treat tumors
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法
JP2021513541A (ja) 2018-02-13 2021-05-27 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗ｐｄ−１抗体によるがんの処置方法
WO2019207030A1 (en) * 2018-04-26 2019-10-31 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting a response with an immune checkpoint inhibitor in a patient suffering from a lung cancer
US12263147B2 (en) * 2018-12-27 2025-04-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Treatment of STK11-loss cancers
WO2020198672A1 (en) * 2019-03-28 2020-10-01 Bristol-Myers Squibb Company Methods of treating tumor
TW202124437A (zh) * 2019-08-19 2021-07-01 美商潘迪恩營運公司 以ｐｄ－１促效劑進行之標靶免疫耐受性
US20240101666A1 (en) 2020-10-23 2024-03-28 Bristol-Myers Squibb Company Lag-3 antagonist therapy for lung cancer
EP4387104A1 (en) 2022-12-13 2024-06-19 LX Semicon Co., Ltd. Analog-to-digital converter and semiconductor device having the same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165422A1 (en) * 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2016081384A1 (en) * 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
WO2004056875A1 (en) 2002-12-23 2004-07-08 Wyeth Antibodies against pd-1 and uses therefor
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
ES2545609T3 (es) 2008-08-25 2015-09-14 Amplimmune, Inc. Composiciones de antagonistas de PD-1 y métodos de uso
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
US20130017199A1 (en) 2009-11-24 2013-01-17 AMPLIMMUNE ,Inc. a corporation Simultaneous inhibition of pd-l1/pd-l2
NO2504364T3 (enExample) 2009-11-24 2018-01-06
SI2699264T1 (en) 2011-04-20 2018-08-31 Medimmune Llc Antibodies and other molecules that bind b7-h1 and pd-1
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AU2013263076B2 (en) * 2012-05-15 2017-08-31 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
JP6742903B2 (ja) * 2013-05-02 2020-08-19 アナプティスバイオ インコーポレイティッド プログラム死−１（ｐｄ−１）に対する抗体
US9676853B2 (en) * 2013-05-31 2017-06-13 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-1
LT3702373T (lt) 2013-09-13 2022-11-10 Beigene Switzerland Gmbh Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai
HUE046249T2 (hu) 2013-12-12 2020-02-28 Shanghai hengrui pharmaceutical co ltd PD-1 antitest, antigén-kötõ fragmense, és gyógyászati alkalmazása
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
DK3149042T3 (da) * 2014-05-29 2019-11-04 Spring Bioscience Corp PD-L1-antistoffer og anvendelser deraf
CN108112254B (zh) 2015-03-13 2022-01-28 西托姆克斯治疗公司 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014165422A1 (en) * 2013-04-02 2014-10-09 Merck Sharp & Dohme Corp. Immunohistochemical assay for detecting expression of programmed death ligand 1 (pd-l1) in tumor tissue
WO2016081384A1 (en) * 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CANCER RES, vol. 74(19_Supplement), JPN6022041354, 2014, pages 105, ISSN: 0005011384 *
CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY (2016 APR.), 100, P.88-98, JPN6021023373, ISSN: 0004886986 *
JULIE BRAHMER: "NIVOLUMAB VERSUS DOCETAXEL IN ADVANCED SQUAMOUS-CELL NON-SMALL-CELL LUNG CANCER", THE NEW ENGLAND JOURNAL OF MEDICINE, vol. VOL:373, NR:2, JPN5019005117, 9 July 2015 (2015-07-09), pages 123 - 135, ISSN: 0004886984 *
MODERN PATHOLOGY (2016), 29, P.753-763, PUBLISHED: 08 APRIL 2016, JPN6021023374, ISSN: 0004886985 *
ONCOIMMUNOLOGY, vol. VOL. 5, NO. 5,, JPN6022041353, March 2016 (2016-03-01), pages 1131379, ISSN: 0005011383 *

Also Published As

Publication number Publication date
JP2022188071A (ja) 2022-12-20
US20200325226A1 (en) 2020-10-15
KR20250107295A (ko) 2025-07-11
US20250382368A1 (en) 2025-12-18
KR20190015408A (ko) 2019-02-13
JP2025081454A (ja) 2025-05-27
CN109476753A (zh) 2019-03-15
US20220315657A1 (en) 2022-10-06
KR20230118713A (ko) 2023-08-11
WO2017210624A1 (en) 2017-12-07
EP3464369A1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
US20220315657A1 (en) Anti-pd-1 antibody for use in a method of treating a tumor
US12528865B2 (en) Treatment of lung cancer using a combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
JP2024063028A (ja) 抗ｐｄ－１抗体を使用するｐｄ－ｌ１陽性黒色腫の処置
JP2024063023A (ja) 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置
US20180155429A1 (en) Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
JP2019517498A (ja) 再発性小細胞肺癌の処置方法において使用するための抗ｐｄ−１抗体
US20240124589A1 (en) Methods of treating urothelial carcinoma using an anti-pd-1 antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200601

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210622

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210916

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220412

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220711

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221004

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230119

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230314